REINACH, Switzerland, August 19 /PRNewswire-FirstCall/ -- Arpida Ltd (SIX: ARPN) announced today its financial results for the six months ending 30 June 2009. Key events 2009 to date - Regulatory setback for intravenous iclaprim in cSSSI in U.S.A. - Strategic options under review - Company restructuring completed Cash and financial investments of CHF 22.7 million at 30 June 2009 CFO Harry Welten, MBA, commented: "Our cost-saving measures have been implemented, resulting in a substantial reduction of the cash burn.

REINACH, Switzerland, May 7 /PRNewswire-FirstCall/ -- The Annual General Meeting of Arpida Ltd (SIX: ARPN) has approved the proposals that were put forward by the Board of Directors. A total of 90 shareholders were present at the meeting that took place in Reinach today.

REINACH, Switzerland, May 7 /PRNewswire-FirstCall/ -- Arpida Ltd.

REINACH, Switzerland, March 17 /PRNewswire-FirstCall/ -- In their press release of 25 February 2009, Arpida communicated that the Board of Directors was in the process of reviewing all the options for the company's future. In preparation of the shareholders' meeting on 7 May 2009, the Board wishes to update shareholders as follows: At the shareholders' meeting, the Board plans to present all available strategic choices, which could include the following options or a combination thereof: - reverse merger with another biotech business - selling iclaprim and related assets - tender offer for the entire company - other options, including a return of capital The Board believes that the currently depressed stock market may value the company as a whole less than the sum of its assets.

REINACH Switzerland, January 19 /PRNewswire-FirstCall/ -- Arpida Ltd. (SWX: ARPN) announces today that it has received a Complete Response Letter from the U.S.